{"product_id":"cjc-1295","title":"CJC-1295","description":"\u003ch2\u003eAbout CJC-1295\u003c\/h2\u003e\n\u003cp\u003eCJC-1295 without DAC, also catalogued as Modified GRF 1-29, is a synthetic 29 residue analogue of the growth hormone releasing factor produced by the hypothalamus. It reproduces the active amino terminal fragment of that peptide while carrying four amino acid substitutions that resist enzymatic breakdown. Peptsche offers it as a lyophilized powder in a sealed vial, made by solid phase synthesis and characterised by chromatography and mass spectrometry. Peptsche supplies CJC-1295 strictly as a research material for controlled laboratory investigation.\u003c\/p\u003e\n\n\u003ch3\u003eAvailable Sizes\u003c\/h3\u003e\n\u003cp\u003eOffered in a single vial configuration, sealed with a butyl closure and crimp.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e5 mg lyophilized CJC-1295 without DAC per vial\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eProduct Specifications\u003c\/h3\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 without DAC, research grade lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eApplication\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn vitro and laboratory research use only. Not for human or veterinary use.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eAppearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWhite to off white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChemical Formula\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e3367.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePending verification. Public chemical registries currently disagree on the assignment for the form without DAC, so Peptsche does not publish a CAS number for this product.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePubChem CID\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/56841945\" target=\"_blank\" rel=\"noopener\"\u003e56841945\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTyr D-Ala Asp Ala Ile Phe Thr Gln Ser Tyr Arg Lys Val Leu Ala Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Leu Ser Arg NH2 (a 29 residue analogue of growth hormone releasing factor)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMod GRF 1-29, Modified GRF (1-29), CJC-1295 no DAC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e99% or greater by HPLC, verified per batch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStore sealed at 2 to 8 °C, protected from heat, light and moisture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use compound. Not approved for human or veterinary use in any jurisdiction. CJC-1295 was withdrawn from consideration on the United States Food and Drug Administration bulk drug substances list.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\n\u003ch2\u003eWhat is CJC-1295?\u003c\/h2\u003e\n\u003cp\u003eGrowth hormone releasing factor is a hypothalamic peptide acting on the anterior pituitary through a class B G protein coupled receptor. The endogenous molecule spans 44 amino acids, but the first 29 carry essentially all of its receptor binding and activating capacity, and that fragment became the scaffold for a family of synthetic analogues.\u003c\/p\u003e\n\u003cp\u003eIts chemical distinction lies in four substitutions at sites recognised by proteases. D-alanine at the second residue removes the principal cleavage point, and the remaining changes limit oxidation and deamidation. The molecule has a free amino terminus and no albumin binding moiety, making it the unconjugated tetrasubstituted analogue, not the drug affinity complex derivative.\u003c\/p\u003e\n\u003cp\u003eThe literature deserves plain statement. No peer reviewed literature studies the form without DAC under that name. The Jetté 2005 paper characterises the unconjugated tetrasubstituted analogue, the parent peptide of the material offered here, while the other cited work used the DAC conjugated form, in which a linker couples the peptide to albumin and gives a very different plasma profile. Researchers should account for this when reading the literature.\u003c\/p\u003e\n\n\u003ch2\u003eCJC-1295 Mechanism of Action (Research Only)\u003c\/h2\u003e\n\u003cp\u003eMechanistic interest here is confined to one receptor system and the modifications altering ligand persistence.\u003c\/p\u003e\n\n\u003ch3\u003eGrowth Hormone Releasing Factor Receptor Agonism\u003c\/h3\u003e\n\u003cp\u003eThe peptide binds the growth hormone releasing factor receptor on somatotroph cells of the anterior pituitary. That receptor belongs to the secretin family and signals through the stimulatory G protein, raising cyclic adenosine monophosphate and activating protein kinase A. Cell based readouts include cyclic nucleotide accumulation and secretory output from pituitary cultures. The amino terminal region activates and the carboxyl terminal helix binds.\u003c\/p\u003e\n\n\u003ch3\u003eFour Amino Acid Substitutions and Enzymatic Resistance\u003c\/h3\u003e\n\u003cp\u003eDipeptidyl peptidase cleaves the first two residues from the native fragment within minutes in serum, giving an inactive product. D-alanine at the second position blocks that reaction because the enzyme active site cannot accommodate the inverted stereocentre. Further substitutions address deamidation and oxidation, so measured concentration tracks nominal concentration closely in stability assays.\u003c\/p\u003e\n\n\u003ch3\u003eAbsence of the Drug Affinity Complex\u003c\/h3\u003e\n\u003cp\u003eThe conjugated derivative carries a maleimidopropionic acid group that reacts with a free cysteine on serum albumin, tethering the peptide to a long lived carrier and extending its plasma residence. The material here lacks that group, so its plasma profile is shorter and receptor exposure is a brief pulse rather than a sustained plateau. This is the key variable when comparing the two forms.\u003c\/p\u003e\n\n\u003ch3\u003eIntegrated Mechanistic Profile\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eReceptor engagement:\u003c\/strong\u003e selective agonism at the growth hormone releasing factor receptor of the pituitary.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eChemical stabilisation:\u003c\/strong\u003e four substitutions confer resistance to enzymatic degradation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShorter plasma profile:\u003c\/strong\u003e absence of the drug affinity complex gives transient rather than sustained exposure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e CJC-1295 is supplied strictly for research use only. It is intended as an experimental compound for qualified laboratory personnel and is not a drug, food or cosmetic.\u003c\/p\u003e\n\u003cp\u003eCJC-1295 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Applications (Observations from Studies)\u003c\/h2\u003e\n\u003cp\u003eThe summaries below describe published research on this class of analogue. They are not statements about the product offered for sale.\u003c\/p\u003e\n\n\u003ch3\u003eReceptor Pharmacology and Binding Studies\u003c\/h3\u003e\n\u003cp\u003eAnalogues of the 29 residue fragment have been used in systems expressing the recombinant receptor to map binding affinity and agonist efficacy, by competition binding and cyclic nucleotide accumulation.\u003c\/p\u003e\n\n\u003ch3\u003eComparative Stability Investigations\u003c\/h3\u003e\n\u003cp\u003eInvestigators incubate the substituted analogue alongside the unmodified fragment in serum or in buffers containing purified peptidases, following loss of parent species by mass spectrometry.\u003c\/p\u003e\n\n\u003ch3\u003eAnalytical Method Development\u003c\/h3\u003e\n\u003cp\u003eBecause the molecule is well defined and highly pure, it serves as a reference standard for laboratories developing quantitative assays for peptides of similar size and for calibrating chromatography methods.\u003c\/p\u003e\n\n\u003cp\u003eCJC-1295 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eCJC-1295 Compared With Related Research Compounds\u003c\/h2\u003e\n\u003cp\u003eThe table below places CJC-1295 alongside two related compounds in the Peptsche range. It is offered to clarify differences in classification, molecular target and research context. It should not be read as a comparison of clinical performance, safety, or suitability for any application.\u003c\/p\u003e\n\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCharacteristic\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCJC-1295\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/ipamorelin\"\u003eIpamorelin\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003ca href=\"\/products\/sermorelin\"\u003eSermorelin\u003c\/a\u003e\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eResearch Classification\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSynthetic 29 residue analogue of growth hormone releasing factor\u003c\/td\u003e\n\u003ctd\u003eSynthetic pentapeptide growth hormone secretagogue\u003c\/td\u003e\n\u003ctd\u003eSynthetic 29 residue fragment of human growth hormone releasing hormone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Molecular Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing factor receptor on pituitary somatotrophs\u003c\/td\u003e\n\u003ctd\u003eGhrelin receptor GHS-R1a on pituitary somatotrophs\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone releasing hormone receptor on pituitary somatotrophs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMechanistic Profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAgonism at the growth hormone releasing hormone receptor, with a brief plasma profile\u003c\/td\u003e\n\u003ctd\u003eAgonism at the ghrelin receptor GHS-R1a, a receptor system separate from the growth hormone releasing hormone receptor\u003c\/td\u003e\n\u003ctd\u003eAgonism at the growth hormone releasing hormone receptor, unmodified parent scaffold\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePrimary Research Focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReceptor pharmacology, comparative stability and analytical method development\u003c\/td\u003e\n\u003ctd\u003ePituitary cell and receptor assays, rodent skeletal endpoints, comparative secretagogue pharmacology\u003c\/td\u003e\n\u003ctd\u003eReference comparator in analogue design, peptide modification chemistry, endocrine signalling models\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStructural Design\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e29 residues with four substitutions, no albumin binding moiety\u003c\/td\u003e\n\u003ctd\u003eFive residues including non standard Aib and D configured aromatic residues, amidated terminus\u003c\/td\u003e\n\u003ctd\u003eResidues 1 to 29 with a terminal amide, one methionine, no unnatural residues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use in any jurisdiction, and withdrawn from consideration on the United States Food and Drug Administration bulk drug substances list\u003c\/td\u003e\n\u003ctd\u003eResearch use compound, not approved for human or veterinary use in any jurisdiction, and placed in Category 2 of the United States Food and Drug Administration list of bulk drug substances\u003c\/td\u003e\n\u003ctd\u003eFormerly the active ingredient in an approved medicine marketed as Geref by EMD Serono, with all products under those applications now discontinued. Material supplied is research grade, is not that former medicine, and is not approved for human or veterinary use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003cp\u003eCJC-1295 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\u003ch2\u003eLaboratory Handling and Storage Considerations\u003c\/h2\u003e\n\u003cp\u003eLyophilized peptide of this length is hygroscopic and takes up moisture once the seal is broken. Vials should reach ambient temperature before opening so condensation does not form on the cold powder. Sealed vials are stable at 2 to 8 °C when kept dry and dark.\u003c\/p\u003e\n\u003cp\u003eIn solution the material is far less stable. Solutions should be sterile filtered, buffered, refrigerated, protected from light and used within a window set by the laboratory's own stability testing. Repeated freezing and thawing causes aggregation, so aliquoting into single use portions is standard. Glass or low binding polypropylene labware is preferred because these peptides adsorb to untreated plastic.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory Safety Considerations\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003ePersonal protective equipment:\u003c\/strong\u003e laboratory coat, nitrile gloves and eye protection whenever the vial is open.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEngineering controls:\u003c\/strong\u003e handle open vials inside a certified fume hood or containment enclosure.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExposure prevention:\u003c\/strong\u003e avoid contact with skin and eyes, do not inhale the powder, never pipette by mouth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e keep sealed at 2 to 8 °C, protected from heat, light and moisture, in a restricted area.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpill response:\u003c\/strong\u003e restrict access, avoid raising dust, collect with a damp wipe, then decontaminate and seal the waste.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisposal:\u003c\/strong\u003e treat unused material and contaminated consumables as chemical laboratory waste under institutional rules.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDocumentation:\u003c\/strong\u003e record lot number, receipt date, storage conditions and quantities used for traceability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCertificate of Analysis and Quality Assurance\u003c\/h2\u003e\n\u003cp\u003eEvery production lot of CJC-1295 supplied by Peptsche undergoes analytical evaluation, and a batch specific Certificate of Analysis accompanies each order to support research documentation, quality control and experimental consistency.\u003c\/p\u003e\n\u003cp\u003eEach Certificate of Analysis typically includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity verification\u003c\/strong\u003e using analytical techniques such as mass spectrometry to confirm the molecular characteristics of the material supplied.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity analysis\u003c\/strong\u003e performed by high performance liquid chromatography to quantify purity and identify potential impurities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBatch documentation\u003c\/strong\u003e recording lot number, testing date, analytical methods applied and quality assessment results.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTraceability information\u003c\/strong\u003e to support laboratory recordkeeping and reproducibility across research workflows.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePeptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification of research material quality. Independent testing provides transparency and confidence in product identity, consistency and sourcing, and batch specific documentation can be retained as part of laboratory records and internal quality procedures.\u003c\/p\u003e\n\u003cp\u003eCJC-1295 is supplied exclusively for laboratory research use and is not intended for human or veterinary application.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is CJC-1295?\u003c\/h3\u003e\n\u003cp\u003eCJC-1295 without DAC, also catalogued as Modified GRF 1-29, is a synthetic 29 residue analogue of the growth hormone releasing factor produced by the hypothalamus. It reproduces the active amino terminal fragment of that peptide while carrying four amino acid substitutions that resist enzymatic breakdown. Peptsche supplies it as a lyophilized powder in a sealed vial for controlled laboratory investigation.\u003c\/p\u003e\n\u003ch3\u003eWhat is CJC-1295 studied for in research?\u003c\/h3\u003e\n\u003cp\u003ePublished work on this class of analogue covers receptor pharmacology and binding studies, comparative stability investigations and analytical method development. Because the molecule is well defined and highly pure, it also serves as a reference standard for laboratories developing quantitative peptide assays. These describe areas of laboratory study rather than established outcomes outside those experimental systems.\u003c\/p\u003e\n\u003ch3\u003eHow does CJC-1295 work in laboratory research?\u003c\/h3\u003e\n\u003cp\u003eIn the systems described in the literature the peptide binds the growth hormone releasing factor receptor on somatotroph cells of the anterior pituitary, a secretin family receptor signalling through the stimulatory G protein. Four amino acid substitutions confer resistance to enzymatic degradation. Because the material carries no albumin binding moiety, receptor exposure is a brief pulse rather than a sustained plateau.\u003c\/p\u003e\n\u003ch3\u003eHow is the quality of Peptsche CJC-1295 verified?\u003c\/h3\u003e\n\u003cp\u003eEvery production lot of Peptsche CJC-1295 is evaluated analytically, with identity confirmed using techniques such as mass spectrometry and purity quantified by high performance liquid chromatography. Peptsche works with Janoshik Analytical, an independent testing laboratory, for third party verification, and a batch specific Certificate of Analysis accompanies each order.\u003c\/p\u003e\n\u003ch3\u003eHow should unopened CJC-1295 be stored?\u003c\/h3\u003e\n\u003cp\u003eUnopened vials should be stored sealed at 2 to 8 °C, protected from heat, light and moisture. Vials should reach ambient temperature before opening so condensation does not form on the cold powder. Lot number, receipt date and storage conditions should be recorded in laboratory documentation so results stay traceable to a batch.\u003c\/p\u003e\n\u003ch3\u003eIs CJC-1295 intended for human use?\u003c\/h3\u003e\n\u003cp\u003eNo. CJC-1295 is supplied strictly for laboratory research use only. It is not approved for human consumption, veterinary use, diagnosis, treatment or any medical application.\u003c\/p\u003e\n\u003ch3\u003eWhy do researchers choose Peptsche for CJC-1295?\u003c\/h3\u003e\n\u003cp\u003ePeptsche supplies CJC-1295 at 99% or greater purity by HPLC, verified per batch, as a lyophilized powder in a vial sealed with a butyl closure and crimp. Each lot is released against batch specific analytical documentation, and independent third party confirmatory analysis supports reproducibility across research workflows.\u003c\/p\u003e\n\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eJetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052 to 3058. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15817669\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/15817669\/\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eTeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799 to 805. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/16352683\/\u003c\/a\u003e (this study examined the DAC conjugated form)\u003c\/li\u003e\n\u003cli\u003eIonescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792 to 4797. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17018654\/\" target=\"_blank\" rel=\"noopener\"\u003ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/17018654\/\u003c\/a\u003e (this study examined the DAC conjugated form)\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2\u003eRESEARCH USE ONLY\u003c\/h2\u003e\n\u003cp\u003eThese compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.\u003c\/p\u003e","brand":"Peptsche","offers":[{"title":"5mg","offer_id":43752784592959,"sku":"PEP-CJC1295-5MG","price":35.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0675\/7394\/0287\/files\/peptsche_CJC1295_5mg.png?v=1786904254","url":"https:\/\/peptsche.com\/products\/cjc-1295","provider":"Peptsche","version":"1.0","type":"link"}